Pyxis Oncology, Inc.

NasdaqGS:PYXS Stock Report

Market Cap: US$191.4m

Pyxis Oncology Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGS:PYXS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Sep 23BuyUS$14,960Pamela ConnealyIndividual8,000US$1.87
27 Sep 23BuyUS$11,868Pamela ConnealyIndividual6,426US$1.85
27 Sep 23BuyUS$4,675Jitendra WadhaneIndividual2,500US$1.87
25 Sep 23BuyUS$20,044Pamela ConnealyIndividual12,000US$1.67
25 Sep 23BuyUS$8,850Jitendra WadhaneIndividual5,000US$1.77
22 Sep 23BuyUS$8,695Pamela ConnealyIndividual5,000US$1.74
22 Sep 23BuyUS$4,349Jitendra WadhaneIndividual2,500US$1.74
18 Sep 23SellUS$18,161Lara SullivanIndividual8,641US$2.25
13 Sep 23SellUS$63,301Lara SullivanIndividual27,917US$2.27

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of PYXS?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds3,170,8035.38%
Individual Insiders3,630,6866.17%
VC/PE Firms4,184,1007.11%
Public Companies8,694,60114.8%
General Public18,559,42331.5%
Institutions20,648,86035.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.2%.


Top Shareholders

Top 25 shareholders own 62.27% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.1%
Pfizer Inc.
5,952,263US$19.3m0%no data
7.38%
Ridgeback Capital Management LLC
4,345,228US$14.1m-27.1%24.23%
7.11%
Deep Track Capital, LP
4,184,100US$13.6m0%0.37%
5.38%
Laurion Capital Management LP
3,170,803US$10.3m-17.9%0.33%
4.66%
Bayer Aktiengesellschaft
2,742,338US$8.9m0%no data
4.41%
Balyasny Asset Management L.P.
2,594,324US$8.4m0%0.03%
3.17%
Lara Sullivan
1,866,547US$6.1m0%no data
3.05%
StemPoint Capital LP
1,794,195US$5.8m0%1.81%
2.82%
Ikarian Capital, LLC
1,662,408US$5.4m0%1.83%
2.38%
The Vanguard Group, Inc.
1,401,425US$4.6m7.25%no data
1.83%
Pfizer Venture Investments LLC
1,080,507US$3.5m0%99.98%
1.2%
abrdn plc
708,303US$2.3m0%no data
0.99%
Millennium Management LLC
583,009US$1.9m4,290%no data
0.9%
Pamela Connealy
529,050US$1.7m-15.3%no data
0.84%
Superstring Capital Management LP
493,759US$1.6m0%1.44%
0.84%
Boothbay Fund Management, LLC
492,462US$1.6m0%0.06%
0.75%
Monashee Investment Management, LLC
442,500US$1.4m0%0.19%
0.65%
Hillhouse Investment Management, Ltd.
382,606US$1.2m0%0.01%
0.64%
John Flavin
377,796US$1.2m0%no data
0.58%
Geode Capital Management, LLC
340,121US$1.1m10.3%no data
0.57%
Goldman Sachs Group, Investment Banking and Securities Investments
336,691US$1.1m0%no data
0.55%
Decheng Capital LLC
326,810US$1.1m0%0.37%
0.55%
BlackRock, Inc.
321,665US$1.0m3.56%no data
0.53%
BNY Asset Management
311,630US$1.0m92.2%no data
0.39%
Bridgeway Capital Management, LLC
231,495US$752.4k0%0.01%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.